(Q43500076)

24 November 2017

title

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia (English)

1 reference

24 November 2017

1 reference

metastatic colon cancer

1 reference

1 reference

1

1 reference

24 November 2017

3

1 reference

24 November 2017

Sabine Tejpar

2

1 reference

24 November 2017

Domenica Mercadante

4

1 reference

24 November 2017

Tracey Teague

5

1 reference

24 November 2017

Bruno Wohlschlegel

6

1 reference

24 November 2017

Eric Van Cutsem

7

1 reference

24 November 2017

publication date

1 June 2011

1 reference

24 November 2017

1 reference

24 November 2017

volume

6

1 reference

24 November 2017

issue

3

1 reference

24 November 2017

page(s)

133-145

1 reference

Future of personalized medicine in oncology: a systems biology approach

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Molecular circuits of solid tumors: prognostic and predictive tools for bedside use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS mutation screening in colorectal cancer: From paper to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-011-0181-X

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice

21 January 2018

1 reference

12 December 2020

Frequency of Ki-ras mutations and DNA alkylation in colorectal tissue from individuals living in Manchester

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

1 reference

12 December 2020

K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients

1 reference

12 December 2020

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment

1 reference

12 December 2020

Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer

1 reference

12 December 2020

10.1007/S11523-011-0181-X

Identifiers

DOI

1 reference

release_cdkl4ongxjhvhpy42jnm74xwt4

24 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cdkl4ongxjhvhpy42jnm74xwt4

24 November 2022

mapped directly with Wikidata item

1 reference